Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 19 of 114

  1. BIIB019 (Daclizumab)

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  2. BIIB059

    Biogen

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. BIIB111

    Biogen

    Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)

    phase 3 small molecule active

    1 trial

  4. BIIB122

    Denali Therapeutics

    Parkinson Disease

    phase 3 small molecule active

    2 trials

  5. BIPAP Synchrony

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 other completed

    1 trial

  6. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  7. BJT-778

    Blue Earth Diagnostics Ireland Ltd

    Chronic Hepatitis Delta Infection

    phase 3 small molecule active

    1 trial

  8. BLU-263-1201

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis and SSM

    phase 3 small molecule active

    1 trial

  9. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IVA (Morquio A Syndrome)

    phase 3 small molecule completed

    1 trial

  10. BMN 110 - Weekly

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IV A

    phase 3 small molecule completed

    1 trial

  11. BMN 110 Weekly

    BioMarin Pharmaceutical Australia Pty Ltd

    MPS IV A

    phase 3 small molecule completed

    1 trial

  12. BMN 111

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    6 trials

  13. BMN 165

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 3 small molecule completed

    1 trial

  14. BMN 333

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial

  15. BMN 701

    BioMarin Pharmaceutical Australia Pty Ltd

    Late-onset Pompe Disease

    phase 3 small molecule terminated

    1 trial

  16. BMN165 20mg/day

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 3 small molecule completed

    1 trial

  17. BMS-986353

    Bristol-Myers Squibb Australia Pty Ltd

    Systemic Sclerosis

    phase 3 small molecule active

    1 trial

  18. BN42082

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  19. BN42083

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  20. BN42358

    Hoffmann-La Roche

    Early Parkinson's disease

    phase 3 small molecule active

    1 trial

  21. BN42644

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 3 other active

    1 trial

  22. BNT323-01

    BioNTech SE

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  23. BNT327-03

    BioNTech SE

    English First-line extensive-stage small-cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  24. BNT327-05

    BioNTech SE

    First line triple-negative breast cancer (TNBC)

    phase 3 small molecule active

    1 trial

  25. BNT327-06

    BioNTech SE

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  26. BO25323

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  27. BO28984

    Hoffmann-La Roche

    Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  28. BO29554

    Hoffmann-La Roche

    Advanced or metastatic Non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  29. BO40336

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  30. BO40729

    Hoffmann-La Roche

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  31. BO41423

    Hoffmann-La Roche

    Mild or moderate hemophilia A without FVIII inhibitors

    phase 3 small molecule active

    1 trial

  32. BO41843

    Hoffmann-La Roche

    ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

    phase 3 small molecule active

    1 trial

  33. BO42161

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  34. BO42162

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  35. BO42592

    Hoffmann-La Roche

    Non-squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  36. BO42777

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  37. BO42843

    Hoffmann-La Roche

    High-risk muscle-invasive bladder cancer

    phase 3 small molecule active

    1 trial

  38. BO42864

    Hoffmann-La Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  39. BO45217

    Hoffmann-La Roche

    KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 other active

    1 trial

  40. BOOG 2010-02 Stop&Go study

    Teva Pharma GmbH

    Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  41. BOTOX

    AbbVie

    Masseter Muscle Prominence

    phase 3 small molecule completed

    1 trial

  42. BP11-301

    CuraTeQ Biologics s.r.o

    Chronic Urticaria

    phase 3 small molecule active

    1 trial

  43. BRADI ICO-2023-15

    CERO THERAPEUTICS HOLDINGS, INC.

    Brain metastases of cancer > brain radionecrosis

    phase 3 small molecule active

    1 trial

  44. BRCA-P/ABCSG 50

    Shanghai Reinovax Biologics Co.,LTD

    Prevention of breast cancer in women with a BRCA1 germline mutation

    phase 3 small molecule active

    1 trial

  45. BT-001

    CATALYST PHARMACEUTICALS, INC.

    Type2 Diabetes

    phase 3 other terminated

    1 trial

  46. BT8009-230

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  47. BT8009-230

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  48. BUL-8/EEA

    Dr. Falk Pharma GmbH

    eosinophilic esophagitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.